Vizgen provides spatial multi-omics platforms enabling researchers to reveal cellular insights through spatial transcriptomics proteomics.
Vizgen has raised $48.0M in total funding. The most recent round was Series E. The last funding was announced in January 2026.
Vizgen's investors include ARCH Venture Partners, Sofina, Novalis LifeSciences, Tao Capital Partners, Pura Vida Investments.
Vizgen is headquartered in Cambridge, United States.
Vizgen provides spatial multi-omics platforms enabling researchers to reveal cellular insights through spatial transcriptomics proteomics.
Vizgen is at the Series E stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vizgen — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/vizgen. Accessed July 21, 2026.
VCBacked. (2026). Vizgen — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/vizgen
{{cite web |title=Vizgen — Funding & Investors |url=https://www.vcbacked.co/company/vizgen |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated